Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
about
Calcofluor white combination antifungal treatments for Trichophyton rubrum and Candida albicansCalcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniaeTherapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin.Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.In vitro susceptibility of Malassezia pachydermatis isolates from canine skin with atopic dermatitis to ketoconazole and itraconazole in East Asia.Identification of GXXXXG motif in Chrysophsin-1 and its implication in the design of analogs with cell-selective antimicrobial and anti-endotoxin activities.Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosisPharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelThe first case of feline sinonasal aspergillosis due to Aspergillus fischeri in JapanIdentification and characterization of an anti-oxidative stress-associated mutant of Aspergillus fumigatus transformed by Agrobacterium tumefaciensThe current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro.Combinatorial strategies for combating invasive fungal infections.Strategies to manage antifungal drug resistance.Neonatal invasive candidiasis in Tunisian hospital: incidence, risk factors, distribution of species and antifungal susceptibility.Pyrrolo[1,2-α][1,4]benzodiazepines show potent in vitro antifungal activity and significant in vivo efficacy in a Microsporum canis dermatitis model in guinea pigs.Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.Agar Diffusion Procedures for Susceptibility Testing of Malassezia pachydermatis: Evaluation of Mueller-Hinton Agar Plus 2 % Glucose and 0.5 µg/ml Methylene Blue as the Test Medium.Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis.Antifungal susceptibility of Malassezia pachydermatis biofilm.Antifungal use influences Candida species distribution and susceptibility in the intensive care unit.Quantification of CDR1 Gene Expression in Fluconazole Resistant Candida Glabrata Strains Using Real-time PCR.In vitro susceptibility testing of Malassezia pachydermatis to gentamicin.Methodological Issues in Antifungal Susceptibility Testing of Malassezia pachydermatis.Susceptibility of Malassezia pachydermatis to aminoglycosides.Evaluation of the antifungal susceptibility of Malassezia pachydermatis to clotrimazole, miconazole and thiabendazole using a modified CLSI M27-A3 microdilution method.Nutrient-Dependent Efficacy of the Antifungal Protein YvgO Correlates to Cellular Proliferation Rate in Candida albicans 3153A and Byssochlamys fulva H25.In vitroevaluation ofMalassezia pachydermatissusceptibility to azole compounds using E-test and CLSI microdilution methodsTherapy and Antifungal Susceptibility Profile of
P2860
Q28481170-5C74C6AF-4A13-45B6-B266-DF83A1DAD01DQ28483234-3CEF1EC2-22BA-4DF3-BC35-2E4C7329AFAEQ33613647-9B1011AA-FADC-45AB-8500-898282387B46Q33622932-BE202296-0DC3-46CD-A3C3-ECF2935AC5D1Q33780430-2AC3223C-E9D1-475B-9F98-D6D229C2170BQ33794227-C7D23352-1695-4256-AAE1-88399874276CQ34737783-BE1D7AF6-6898-490C-AAF3-09B1D22A4EACQ35666627-E68DAC3F-B282-4A63-8E52-AF633305884CQ36113401-9DAB6994-40CD-4BDB-A117-55878D6A6FA4Q36624069-28AB86DD-B4DD-4B9E-93F4-C309BFED77F4Q37700546-6E14B208-75C0-417D-9EF9-34022BFF2D8AQ37705303-A8DF2926-9590-420F-851B-D6D157D1B25CQ37827872-E1CBAB5B-2044-4810-A664-0C51208A7842Q38901652-AE9AFC83-5709-454D-9EE6-DB71B4CDB8FDQ39023107-2AC81041-C0FF-4322-8A80-102CDE3EEEDDQ40337564-8C5B7F36-34A2-4FCB-AF7A-09CFE0703386Q41126248-D98A51B4-19D5-4314-83E1-81F41FA6EBC3Q41543735-80AADF92-2AD2-4FDB-9BB8-FE5FA25D8776Q44432483-3902D380-0B89-4EDC-AADB-66B0739B1E67Q45988034-C5649F1C-B826-4A19-82F2-026284B484F5Q46086583-0A5D2EA1-918A-480C-A1CB-23519728BD1CQ47427448-25538500-00B7-4BAB-A688-43A29AA61A0FQ47711304-32855DE2-6ED7-4B26-ABE0-63617B4A73F6Q48326049-E7FCAC75-220B-4E77-B90C-9E44C47D3132Q50968796-53B85604-33D5-4141-B166-6254F534B1D8Q53447392-90FA42F3-5501-4985-9EF6-2C7352156B94Q56958345-F9FF5381-B978-4715-9B27-DBB5614F6B53Q58762553-EA177632-C901-4D34-9948-50D4FC62B6F6
P2860
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
@en
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
@nl
type
label
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
@en
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
@nl
prefLabel
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
@en
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
@nl
P2093
P2860
P356
P1476
Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
@en
P2093
Ana Espinel-Ingroff
Emilia Cantón
Javier Pemán
P2860
P304
P356
10.1586/14787210.7.1.107
P577
2009-02-01T00:00:00Z